The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial

Publication date: Available online 6 April 2020Source: European UrologyAuthor(s): David P. Dearnaley, Daniel R. Saltzstein, John E. Sylvester, Lawrence Karsh, Bryan A. Mehlhaff, Christopher Pieczonka, James L. Bailen, Hongliang Shi, Zhan Ye, Hélène M. Faessel, Huamao Lin, Yanyan Zhu, Fred Saad, David B. MacLean, Neal D. Shore
Source: European Urology - Category: Urology & Nephrology Source Type: research